DOSE — Rapid Dose Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$30.33m
- CA$32.92m
- CA$2.09m
Annual cashflow statement for Rapid Dose Therapeutics, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.
2021 February 28th | 2022 February 28th | 2023 February 28th | 2024 February 29th | 2025 February 28th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.3 | -8.49 | -3.81 | -4.31 | -5.4 |
| Depreciation | |||||
| Non-Cash Items | 0.07 | 5.92 | 0.751 | 0.903 | 2.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.071 | -1.2 | 1.57 | 0.489 | 1.52 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.62 | -3 | -0.864 | -2.29 | -1.15 |
| Capital Expenditures | -0.009 | -0.04 | 0 | — | -0.006 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 1.9 | 0 | — | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.009 | 1.85 | 0 | — | -0.006 |
| Financing Cash Flow Items | -0.087 | 0.13 | 0.253 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.65 | 1.13 | 0.857 | 2.43 | 1.01 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.067 | -0.036 | -0.007 | 0.133 | -0.14 |